Loading
Fyarro is an infusion of the transplant drug sirolimus packaged in albumin particles. It is the first approved treatment for malignant PEComa, a rare soft-tissue tumour driven by loss of the TSC genes.
Sirolimus protein-bound particles were approved by the FDA in November 2021 for adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa), on the AMPECT single-arm trial in which 39% of 31 patients responded, with responses concentrated in tumours carrying TSC2 inactivation and several lasting over two years. The albumin formulation allows higher intratumoural drug exposure than oral rapalogues. It is being studied in other TSC1/2-altered solid tumours (PRECISION 1). Stomatitis, myelosuppression, hyperglycaemia, hyperlipidaemia and pneumonitis are the mTOR-class effects.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Sirolimus bound to albumin nanoparticles; binds FKBP12 and allosterically inhibits mTORC1, the kinase left unrestrained by the TSC1/TSC2 loss that drives PEComa. Connects to mTOR.
1.Sirolimus protein-bound particles slips into a pocket on mTOR.
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Locally advanced unresectable or metastatic malignant PEComa |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sirolimus protein-bound particles" OR ABSTRACT:"Sirolimus protein-bound particles" OR TITLE:"Fyarro" OR ABSTRACT:"Fyarro" OR TITLE:"nab-sirolimus" OR ABSTRACT:"nab-sirolimus" OR TITLE:"ABI-009" OR ABSTRACT:"ABI-009" OR TITLE:"Nanoparticle albumin-bound rapamycin" OR ABSTRACT:"Nanoparticle albumin-bound rapamycin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sirolimus protein-bound particles, not a curated reading list.
Shares AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours, Perivascular epithelioid cell tumour (PEComa), Sarcomas (soft tissue, bone, GIST).
Shares Temsirolimus, mTOR, Everolimus.
Shares mTOR, Everolimus, PI3K / AKT / mTOR.
Shares Temsirolimus, mTOR, Everolimus, PI3K / AKT / mTOR.
Shares Sirolimus, Everolimus.
Shares Temsirolimus, mTOR.
Shares Epithelioid haemangioendothelioma, Perivascular epithelioid cell tumour (PEComa), Sarcomas (soft tissue, bone, GIST).